NCT05167175 - The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2024

Conditions

Prostate CancerProstate CarcinomaMetastatic Prostate Cancer

Interventions

DRUG

Olaparib tablet

Lynparza (Olaparib tablets) 300 mg should be taken orally twice daily.

DRUG

Abiraterone acetate

Qingkeshu (Abiraterone acetate tablets) 1000 mg should be taken orally once daily.

DRUG

Prednisone tablet

Prednisone Tablets should be taken 5 mg once daily.

Trial Locations (1)

RECRUITING

Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Nanjing